The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 12, 2022

Primary Completion Date

March 12, 2024

Study Completion Date

May 1, 2025

Conditions

Early Low Rectal Cancer

Interventions

DRUG

PD-1 antibody

PD-1 antibody (Toripalimab): 240mg d1 q3w

DRUG

Capecitabine

Capecitabine: 1000mg/m2 d1-14 q3w

DRUG

Oxaliplatin

Oxaliplatin: 130mg/m2 d1 q3w

RADIATION

Short-course radiotherapy

Shor-course radiotherapy: 25Gy/5Fx

Trial Locations (1)

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER